Search

Your search keyword '"Lavilla-Rubira, Esperanza"' showing total 39 results
Start Over Author "Lavilla-Rubira, Esperanza"
39 results on '"Lavilla-Rubira, Esperanza"'

1. Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group

Author

Sargas, Claudia, Ayala, Rosa, Larráyoz, María J., Chillón, María C., Rodriguez-Arboli, Eduardo, Bilbao, Cristina, Prados de la Torre, Esther, Martínez-Cuadrón, David, Rodríguez-Veiga, Rebeca, Boluda, Blanca, Gil, Cristina, Bernal, Teresa, Bergua, Juan, Algarra, Lorenzo, Tormo, Mar, Martínez-Sánchez, Pilar, Soria, Elena, Serrano, Josefina, Alonso-Dominguez, Juan M., García, Raimundo, Amigo, María Luz, Herrera-Puente, Pilar, Sayas, María J., Lavilla-Rubira, Esperanza, Martínez-López, Joaquín, Calasanz, María J., García-Sanz, Ramón, Pérez-Simón, José A., Gómez Casares, María T., Sánchez-García, Joaquín, Barragán, Eva, and Montesinos, Pau

Published
2023
Full Text
View/download PDF

2. Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry

Author

Marchesi, Francesco, Salmanton-García, Jon, Buquicchio, Caterina, Itri, Federico, Besson, Caroline, Dávila-Valls, Julio, Martín-Pérez, Sonia, Fianchi, Luana, Rahimli, Laman, Tarantini, Giuseppe, Grifoni, Federica Irene, Sciume, Mariarita, Labrador, Jorge, Cordoba, Raul, López-García, Alberto, Fracchiolla, Nicola S., Farina, Francesca, Ammatuna, Emanuele, Cingolani, Antonella, García-Bordallo, Daniel, Gräfe, Stefanie K., Bilgin, Yavuz M., Dargenio, Michelina, González-López, Tomás José, Guidetti, Anna, Lahmer, Tobias, Lavilla-Rubira, Esperanza, Méndez, Gustavo-Adolfo, Prezioso, Lucia, Schönlein, Martin, Van Doesum, Jaap, Wolf, Dominik, Hersby, Ditte Stampe, Magyari, Ferenc, Van Praet, Jens, Petzer, Verena, Tascini, Carlo, Falces-Romero, Iker, Glenthøj, Andreas, Cornely, Oliver A., and Pagano, Livio

Published
2023
Full Text
View/download PDF

3. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

Author

Martín-Vallejo, Francisco Javier, Zdziarski, Przemyslaw, Zarrinfer, Hossein, Wittig, Jana, Win, Sein, Wai-Man, Vivien, Víšek, Benjamín, Vinh, Donald C., Vehreschild, Maria, Varricchio, Gina, Tsirigotis, Panagiotis, Torres-Tienza, Ana, Tanase, Alina Daniela, Tafuri, Agostino, Stamouli, Maria, Sramek, Jiří, Soussain, Carole, Shirinova, Ayten, Schubert, Jörg, Schalk, Enrico, Salehi, Mohammad Reza, Saleh, Modar, Rosati, Giorgio, Roldán, Elisa, Reizine, Florian, Rêgo, Mayara, Regalado-Artamendi, Isabel, Popova, Marina, Pinto, Fernando, Philippe, Laure, Orth, Hans Martin, Ommen, Hans-Beier, Obr, Aleš, Núñez-Martín-Buitrago, Lucía, Noël, Nicolas, Neuhann, Julia, Nadali, Gianpaolo, Nacov, Julia A., Munhoz Alburquerque, Ana M., Mitra, Maria Enza, Mikulska, Malgorzata, Mellinghoff, Sibylle, Mechtel, Ben, Martín-González, Juan-Alberto, Malak, Sandra, Loureiro-Amigo, Jorge, Lorenzo De La Peña, Lisset, Liberti, Giulia, Landau, Marianne, Lacej, Ira, Kolditz, Martin, Kho, Chi Shan, Khedr, Reham Abdelaziz, Karthaus, Meinolf, Karlsson, Linda Katharina, Jiménez-Lorenzo, María-Josefa, Izuzquiza, Macarena, Hoell-Neugebauer, Baerbel, Herbrecht, Raoul, Heath, Christopher H., Guolo, Fabio, Grothe, Jan, Giordano, Antonio, Gerasymchuk, Sergey, García-Sanz, Ramón, García-Poutón, Nicole, Funke, Vaneuza Araújo Moreira, Fung, Monica, Flasshove, Charlotte, Fianchi, Luana, Essame, Jenna, Egger, Matthias, Drenou, Bernard, Dragonetti, Giulia, Desole, Maximilian, Della Pepa, Roberta, Deau Fischer, Bénédicte, De Kort, Elizabeth, De Cabo, Erik, Danion, François, Daguindau, Etienne, Cushion, Tania, Cremer, Louise, Criscuolo, Marianna, Cordini, Gregorio, Cingolani, Antonella, Ciceri, Fabio, Chowdhury, Fazle Rabbi, Chelysheva, Ekaterina, Chauchet, Adrien, Chai, Louis Yi Ann, Ceesay, M. Mansour, Busch, Elena, Brehon, Mathias, Borducchi, Davimar M.M., Booth, Stephen, Bologna, Serge, Berg Venemyr, Caroline, Bailén-Almorox, Rebeca, Antoniadou, Anastasia, Anastasopoulou, Amalia N., Altuntaş, Fevzi, Salmanton-García, Jon, Marchesi, Francesco, Farina, Francesca, Weinbergerová, Barbora, Itri, Federico, Dávila-Valls, Julio, Martín-Pérez, Sonia, Glenthøj, Andreas, Hersby, Ditte Stampe, Gomes Da Silva, Maria, Nunes Rodrigues, Raquel, López-García, Alberto, Córdoba, Raúl, Bilgin, Yavuz M., Falces-Romero, Iker, El-Ashwah, Shaimaa, Emarah, Ziad, Besson, Caroline, Kohn, Milena, Van Doesum, Jaap, Ammatuna, Emanuele, Marchetti, Monia, Labrador, Jorge, Zambrotta, Giovanni Paolo Maria, Verga, Luisa, Jaksic, Ozren, Nucci, Marcio, Piukovics, Klára, Cabirta-Touzón, Alba, Jiménez, Moraima, Arellano, Elena, Espigado, Ildefonso, Blennow, Ola, Nordlander, Anna, Meers, Stef, Vian Praet, Jens, Aiello, Tommaso Francesco, Garcia-Vidal, Carolina, Fracchiolla, Nicola S., Sciumè, Mariarita, Seval, Guldane Cengiz, Žák, Pavel, Buquicchio, Caterina, Tascini, Carlo, Gräfe, Stefanie K., Schönlein, Martin, Adžić-VUKIČEVIĆ, Tatjana, Bonuomo, Valentina, Cattaneo, Chiara, Nizamuddin, Summiya, Čerňan, Martin, Plantefeve, Gaëtan, Prin, Romane, Szotkovski, Tomas, Collins, Graham P., Dargenio, Michelina, Petzer, Verena, Wolf, Dominik, Čolović, Natasha, Prezioso, Lucia, Valković, Toni, Passamonti, Francesco, Méndez, Gustavo-Adolfo, Sili, Uluhan, Vena, Antonio, Bavastro, Martina, Limongelli, Alessandro, Duarte, Rafael F., Ledoux, Marie-Pierre, Cvetanoski, Milche, Stojanoski, Zlate, Machado, Marina, Batinić, Josip, Magliano, Gabriele, Biernat, Monika M., Pantić, Nikola, Poulsen, Christian Bjørn, Cuccaro, Annarosa, Del Principe, Maria Ilaria, Kulasekararaj, Austin, Ormazabal-Vélez, Irati, Busca, Alessandro, Demirkan, Fatih, Ijaz, Marriyam, Klimko, Nikolai, Stoma, Igor, Khostelidi, Sofya, Fernández, Noemí, Omrani, Ali S., Bergantim, Rui, De Jonge, Nick, Fouquet, Guillemette, Navrátil, Milan, Abu-Zeinah, Ghaith, Samarkos, Michail, Maertens, Johan, De Ramón, Cristina, Guidetti, Anna, Magyari, Ferenc, González-López, Tomás José, Lahmer, Tobias, Finizio, Olimpia, Ali, Natasha, Pinczés, László Imre, Lavilla-Rubira, Esperanza, Romano, Alessandra, Merelli, Maria, Delia, Mario, Calbacho, Maria, Meletiadis, Joseph, Antić, Darko, Hernández-Rivas, José-Ángel, Marques De Almeida, Joyce, Al-Khabori, Murtadha, Hoenigl, Martin, Tisi, Maria Chiara, Khanna, Nina, Barać, Aleksandra, Eisa, Noha, Di Blasi, Roberta, Liévin, Raphaël, Miranda-Castillo, Carolina, Bahr, Nathan C., Lamure, Sylvain, Papa, Mario Virgilio, Yahya, Ayel, Aujayeb, Avinash, Novák, Jan, Erben, Nurettin, Fernández-Galán, María, Ribera-Santa Susana, José-María, Rinaldi, Ikhwan, Fazzi, Rita, Piedimonte, Monica, Duléry, Rémy, Gonzaga, Yung, Soto-Silva, Andrés, Sapienza, Giuseppe, Serris, Alexandra, Drgoňa, Ľuboš, Groh, Ana, Serrano, Laura, Gavriilaki, Eleni, Tragiannidis, Athanasios, Prattes, Juergen, Coppola, Nicola, Otašević, Vladimir, Mladenović, Miloš, Mitrović, Mirjana, Mišković, Bojana, Jindra, Pavel, Zompi, Sofia, Sacchi, Maria Vittoria, Krekeler, Carolin, Shumilov, Evgenii, Infante, Maria Stefania, García-Bordallo, Daniel, Çolak, Gökçe Melis, Mayer, Jiří, Nygaard, Marietta, Hanáková, Michaela, Ráčil, Zdeněk, Quattrone, Martina, Bonanni, Matteo, Koehler, Philipp, Rahimli, Laman, Cornely, Oliver A., and Pagano, Livio

Published
2024
Full Text
View/download PDF

4. MOLNUPIRAVIR COMPARED TO NIRMATRELVIR/RITONAVIR FOR COVID-19 IN HIGH-RISK PATIENTS WITH HAEMATOLOGICAL MALIGNANCY IN EUROPE. A MATCHED-PAIRED ANALYSIS FROM THE EPICOVIDEHA REGISTRY

Author

SALMANTON-GARCÍA, Jon, MARCHESI, Francesco, KOEHLER, Philipp, WEINBERGEROVÁ, Barbora, ČOLOVIĆ, Natasa, FALCES-ROMERO, Iker, BUQUICCHIO, Caterina, FARINA, Francesca, PRAET, Jens VAN, BIERNAT, Monika M., ITRI, Federico, PREZIOSO, Lucia, TASCINI, Carlo, VENA, Antonio, ROMANO, Alessandra, DELIA, Mario, DÁVILA-VALLS, Julio, MARTÍN-PÉREZ, Sonia, LAVILLA-RUBIRA, Esperanza, ADŽIĆ-VUKIČEVIĆ, Tatjana, GARCÍA-BORDALLO, Daniel, LÓPEZ-GARCÍA, Alberto, CRISCUOLO, Mariana, PETZER, Verena, FRACCHIOLLA, Nicola S., ESPIGADO, Ildefonso, SILI, Uluhan, MEERS, Stef, ERBEN, Nurettin, CATTANEO, Chiara, TRAGIANNIDIS, Athanasios, GAVRIILAKI, Eleni, SCHÖNLEIN, Martin, MITROVIC, Mirjana, PANTIC, Nikola, MERELLI, Maria, LABRADOR, Jorge, HERNÁNDEZ-RIVAS, José-Ángel, GLENTHØJ, Andreas, FOUQUET, Guillemette, DEL PRINCIPE, Maria Ilaria, DARGENIO, Michelina, CALBACHO, María, BESSON, Caroline, KOHN, Milena, GRÄFE, Stefanie, HERSBY, Ditte Stampe, ARELLANO, Elena, MelisÇOLAK, Gökçe, WOLF, Dominik, MARCHETTI, Monia, NORDLANDER, Anna, BLENNOW, Ola, CORDOBA, Raul, MIŠKOVIĆ, Bojana, MLADENOVIĆ, Miloš, BAVASTRO, Martina, LIMONGELLI, Alessandro, RAHIMLI, Laman, PAGANO, Livio, and CORNELY, Oliver A.

Published
2023
Full Text
View/download PDF

5. Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry

Author

Hernández-Boluda, Juan-Carlos, Martínez-Cuadrón, David, Pereira, Arturo, Rodríguez-Veiga, Rebeca, Boluda, Blanca, Gil, Cristina, Casal-Marini, Sandra, Serrano, Josefina, Martínez-López, Joaquín, Bergua, Juan, Algarra, Lorenzo, Bernal, Teresa, López-Lorenzo, Jose-Luis, Colorado, Mercedes, López, Aurelio, Tormo, Mar, Sayas, María-José, Trigo, Fernanda, López-Pavía, María, Pérez-Simón, José-Antonio, Lavilla-Rubira, Esperanza, Rodríguez-Medina, Carlos, Rodríguez-Gutiérrez, Juan-Ignacio, Sanz-Caballer, Miguel-Angel, and Montesinos, Pau

Published
2022
Full Text
View/download PDF

6. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study

Author

Martínez-Cuadrón, David, Megías-Vericat, Juan E., Serrano, Josefina, Martínez-Sánchez, Pilar, Rodríguez-Arbolí, Eduardo, Gil, Cristina, Aguiar, Eliana, Bergua, Juan, López-Lorenzo, José L., Bernal, Teresa, Espadana, Ana, Colorado, Mercedes, Rodríguez-Medina, Carlos, López-Pavía, María, Tormo, Mar, Algarra, Lorenzo, Amigo, María-Luz, Sayas, María J., Labrador, Jorge, Rodríguez-Gutiérrez, Juan I., Benavente, Celina, Costilla-Barriga, Lissette, García-Boyero, Raimundo, Lavilla-Rubira, Esperanza, Vives, Susana, Herrera, Pilar, García-Belmonte, Daniel, Herráez, María Mar, Vasconcelos Esteves, Graça, Gómez-Roncero, Maria I., Cabello, Ana, Bautista, Guiomar, Balerdi, Amaia, Mariz, José, Boluda, Blanca, Sanz, Miguel Á., and Montesinos, Pau

Published
2022
Full Text
View/download PDF

7. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

Author

Salmanton-García, Jon, primary, Marchesi, Francesco, additional, Farina, Francesca, additional, Weinbergerová, Barbora, additional, Itri, Federico, additional, Dávila-Valls, Julio, additional, Martín-Pérez, Sonia, additional, Glenthøj, Andreas, additional, Hersby, Ditte Stampe, additional, Gomes Da Silva, Maria, additional, Nunes Rodrigues, Raquel, additional, López-García, Alberto, additional, Córdoba, Raúl, additional, Bilgin, Yavuz M., additional, Falces-Romero, Iker, additional, El-Ashwah, Shaimaa, additional, Emarah, Ziad, additional, Besson, Caroline, additional, Kohn, Milena, additional, Van Doesum, Jaap, additional, Ammatuna, Emanuele, additional, Marchetti, Monia, additional, Labrador, Jorge, additional, Zambrotta, Giovanni Paolo Maria, additional, Verga, Luisa, additional, Jaksic, Ozren, additional, Nucci, Marcio, additional, Piukovics, Klára, additional, Cabirta-Touzón, Alba, additional, Jiménez, Moraima, additional, Arellano, Elena, additional, Espigado, Ildefonso, additional, Blennow, Ola, additional, Nordlander, Anna, additional, Meers, Stef, additional, Vian Praet, Jens, additional, Aiello, Tommaso Francesco, additional, Garcia-Vidal, Carolina, additional, Fracchiolla, Nicola S., additional, Sciumè, Mariarita, additional, Seval, Guldane Cengiz, additional, Žák, Pavel, additional, Buquicchio, Caterina, additional, Tascini, Carlo, additional, Gräfe, Stefanie K., additional, Schönlein, Martin, additional, Adžić-VUKIČEVIĆ, Tatjana, additional, Bonuomo, Valentina, additional, Cattaneo, Chiara, additional, Nizamuddin, Summiya, additional, Čerňan, Martin, additional, Plantefeve, Gaëtan, additional, Prin, Romane, additional, Szotkovski, Tomas, additional, Collins, Graham P., additional, Dargenio, Michelina, additional, Petzer, Verena, additional, Wolf, Dominik, additional, Čolović, Natasha, additional, Prezioso, Lucia, additional, Valković, Toni, additional, Passamonti, Francesco, additional, Méndez, Gustavo-Adolfo, additional, Sili, Uluhan, additional, Vena, Antonio, additional, Bavastro, Martina, additional, Limongelli, Alessandro, additional, Duarte, Rafael F., additional, Ledoux, Marie-Pierre, additional, Cvetanoski, Milche, additional, Stojanoski, Zlate, additional, Machado, Marina, additional, Batinić, Josip, additional, Magliano, Gabriele, additional, Biernat, Monika M., additional, Pantić, Nikola, additional, Poulsen, Christian Bjørn, additional, Cuccaro, Annarosa, additional, Del Principe, Maria Ilaria, additional, Kulasekararaj, Austin, additional, Ormazabal-Vélez, Irati, additional, Busca, Alessandro, additional, Demirkan, Fatih, additional, Ijaz, Marriyam, additional, Klimko, Nikolai, additional, Stoma, Igor, additional, Khostelidi, Sofya, additional, Fernández, Noemí, additional, Omrani, Ali S., additional, Bergantim, Rui, additional, De Jonge, Nick, additional, Fouquet, Guillemette, additional, Navrátil, Milan, additional, Abu-Zeinah, Ghaith, additional, Samarkos, Michail, additional, Maertens, Johan, additional, De Ramón, Cristina, additional, Guidetti, Anna, additional, Magyari, Ferenc, additional, González-López, Tomás José, additional, Lahmer, Tobias, additional, Finizio, Olimpia, additional, Ali, Natasha, additional, Pinczés, László Imre, additional, Lavilla-Rubira, Esperanza, additional, Romano, Alessandra, additional, Merelli, Maria, additional, Delia, Mario, additional, Calbacho, Maria, additional, Meletiadis, Joseph, additional, Antić, Darko, additional, Hernández-Rivas, José-Ángel, additional, Marques De Almeida, Joyce, additional, Al-Khabori, Murtadha, additional, Hoenigl, Martin, additional, Tisi, Maria Chiara, additional, Khanna, Nina, additional, Barać, Aleksandra, additional, Eisa, Noha, additional, Di Blasi, Roberta, additional, Liévin, Raphaël, additional, Miranda-Castillo, Carolina, additional, Bahr, Nathan C., additional, Lamure, Sylvain, additional, Papa, Mario Virgilio, additional, Yahya, Ayel, additional, Aujayeb, Avinash, additional, Novák, Jan, additional, Erben, Nurettin, additional, Fernández-Galán, María, additional, Ribera-Santa Susana, José-María, additional, Rinaldi, Ikhwan, additional, Fazzi, Rita, additional, Piedimonte, Monica, additional, Duléry, Rémy, additional, Gonzaga, Yung, additional, Soto-Silva, Andrés, additional, Sapienza, Giuseppe, additional, Serris, Alexandra, additional, Drgoňa, Ľuboš, additional, Groh, Ana, additional, Serrano, Laura, additional, Gavriilaki, Eleni, additional, Tragiannidis, Athanasios, additional, Prattes, Juergen, additional, Coppola, Nicola, additional, Otašević, Vladimir, additional, Mladenović, Miloš, additional, Mitrović, Mirjana, additional, Mišković, Bojana, additional, Jindra, Pavel, additional, Zompi, Sofia, additional, Sacchi, Maria Vittoria, additional, Krekeler, Carolin, additional, Shumilov, Evgenii, additional, Infante, Maria Stefania, additional, García-Bordallo, Daniel, additional, Çolak, Gökçe Melis, additional, Cingolani, Antonella, additional, Mayer, Jiří, additional, Criscuolo, Marianna, additional, Nygaard, Marietta, additional, Hanáková, Michaela, additional, Fianchi, Luana, additional, Ráčil, Zdeněk, additional, Giordano, Antonio, additional, Quattrone, Martina, additional, Bonanni, Matteo, additional, Koehler, Philipp, additional, Rahimli, Laman, additional, Cornely, Oliver A., additional, Pagano, Livio, additional, Martín-Vallejo, Francisco Javier, additional, Zdziarski, Przemyslaw, additional, Zarrinfer, Hossein, additional, Wittig, Jana, additional, Win, Sein, additional, Wai-Man, Vivien, additional, Víšek, Benjamín, additional, Vinh, Donald C., additional, Vehreschild, Maria, additional, Varricchio, Gina, additional, Tsirigotis, Panagiotis, additional, Torres-Tienza, Ana, additional, Tanase, Alina Daniela, additional, Tafuri, Agostino, additional, Stamouli, Maria, additional, Sramek, Jiří, additional, Soussain, Carole, additional, Shirinova, Ayten, additional, Schubert, Jörg, additional, Schalk, Enrico, additional, Salehi, Mohammad Reza, additional, Saleh, Modar, additional, Rosati, Giorgio, additional, Roldán, Elisa, additional, Reizine, Florian, additional, Rêgo, Mayara, additional, Regalado-Artamendi, Isabel, additional, Popova, Marina, additional, Pinto, Fernando, additional, Philippe, Laure, additional, Orth, Hans Martin, additional, Ommen, Hans-Beier, additional, Obr, Aleš, additional, Núñez-Martín-Buitrago, Lucía, additional, Noël, Nicolas, additional, Neuhann, Julia, additional, Nadali, Gianpaolo, additional, Nacov, Julia A., additional, Munhoz Alburquerque, Ana M., additional, Mitra, Maria Enza, additional, Mikulska, Malgorzata, additional, Mellinghoff, Sibylle, additional, Mechtel, Ben, additional, Martín-González, Juan-Alberto, additional, Malak, Sandra, additional, Loureiro-Amigo, Jorge, additional, Lorenzo De La Peña, Lisset, additional, Liberti, Giulia, additional, Landau, Marianne, additional, Lacej, Ira, additional, Kolditz, Martin, additional, Kho, Chi Shan, additional, Khedr, Reham Abdelaziz, additional, Karthaus, Meinolf, additional, Karlsson, Linda Katharina, additional, Jiménez-Lorenzo, María-Josefa, additional, Izuzquiza, Macarena, additional, Hoell-Neugebauer, Baerbel, additional, Herbrecht, Raoul, additional, Heath, Christopher H., additional, Guolo, Fabio, additional, Grothe, Jan, additional, Gerasymchuk, Sergey, additional, García-Sanz, Ramón, additional, García-Poutón, Nicole, additional, Funke, Vaneuza Araújo Moreira, additional, Fung, Monica, additional, Flasshove, Charlotte, additional, Essame, Jenna, additional, Egger, Matthias, additional, Drenou, Bernard, additional, Dragonetti, Giulia, additional, Desole, Maximilian, additional, Della Pepa, Roberta, additional, Deau Fischer, Bénédicte, additional, De Kort, Elizabeth, additional, De Cabo, Erik, additional, Danion, François, additional, Daguindau, Etienne, additional, Cushion, Tania, additional, Cremer, Louise, additional, Cordini, Gregorio, additional, Ciceri, Fabio, additional, Chowdhury, Fazle Rabbi, additional, Chelysheva, Ekaterina, additional, Chauchet, Adrien, additional, Chai, Louis Yi Ann, additional, Ceesay, M. Mansour, additional, Busch, Elena, additional, Brehon, Mathias, additional, Borducchi, Davimar M.M., additional, Booth, Stephen, additional, Bologna, Serge, additional, Berg Venemyr, Caroline, additional, Bailén-Almorox, Rebeca, additional, Antoniadou, Anastasia, additional, Anastasopoulou, Amalia N., additional, and Altuntaş, Fevzi, additional

Published
2024
Full Text
View/download PDF

8. Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?

Author

Martínez-Cuadrón, David, Serrano, Josefina, Gil, Cristina, Tormo, Mar, Martínez-Sánchez, Pilar, Pérez-Simón, José A., García-Boyero, Raimundo, Rodríguez-Medina, Carlos, López-Pavía, María, Benavente, Celina, Bergua, Juan, Lavilla-Rubira, Esperanza, Amigo, María L., Herrera, Pilar, Alonso-Domínguez, Juan M., Bernal, Teresa, Colorado, Mercedes, Sayas, María J., Algarra, Lorenzo, Vidriales, María B., Rodríguez-Macías, Gabriela, Vives, Susana, Pérez-Encinas, Manuel M., López, Aurelio, Noriega, Víctor, García-Fortes, María, Ramos, Fernando, Rodríguez-Gutiérrez, Juan I., Costilla-Barriga, Lisette, Labrador, Jorge, Boluda, Blanca, Rodríguez-Veiga, Rebeca, Martínez-López, Joaquín, Sanz, Miguel A., and Montesinos, Pau

Published
2021
Full Text
View/download PDF

9. Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022

Author

Arellano-Orden, Elena [0000-0003-0581-8947], Salmanton-García, Jon, Marchesi, Francesco, Farina, Francesca, Weinbergerová, Barbora, Itri, Federico, Dávila-Valls, Julio, Martín-Pérez, Sonia, Glenthøj, Andreas, Hersby, Ditte Stampe, Gomes da Silva, Maria, Nunes Rodrigues, Raquel, López-García, Alberto, Córdoba, Raúl, Bilgin, Yavuz M., Falces-Romero, Iker, El-Ashwah, Shaimaa, Emarah, Ziad, Besson, Caroline, Kohn, Milena, Van Doesum, Jaap, Ammatuna, Emanuele, Marchetti, Monia, Labrador, Jorge, Zambrotta, Giovanni Paolo Maria, Verga, Luisa, Jaksic, Ozren, Nucci, Marcio, Piukovics, Klára, Cabirta-Touzón, Alba, Jiménez, Moraima, Arellano-Orden, Elena, Espigado, Ildefonso, Blennow, Ola, Nordlander, Anna, Meers, Stef, van Praet, Jens, Aiello, Tommaso Francesco, Garcia-Vidal, Carolina, Fracchiolla, Nicola, Sciumè, Mariarita, Seval, Guldane Cengiz, Žák, Pavel, Buquicchio, Caterina, Tascini, Carlo, Gräfe, Stefanie K., Schönlein, Martin, Adžić-Vukičević, Tatjana, Bonuomo, Valentina, Cattaneo, Chiara, Nizamuddin, Summiya, Čerňan, Martin, Plantefeve, Gaëtan, Prin, Romane, Szotkovski, Tomas, Collins, Graham P., Dargenio, Michelina, Petzer, Verena, Wolf, Dominik, Čolović, Natasha, Prezioso, Lucia, Valković, Toni, Passamonti, Francesco, Méndez, Gustavo-Adolfo, Sili, Uluhan, Vena, Antonio, Bavastro, Martina, Limongelli, Alessandro, Duarte, Rafael F., Ledoux, Marie-Pierre, Cvetanoski, Milche, Stojanoski, Zlate, Machado, Marina, Batinić, Josip, Magliano, Gabriele, Biernat, Monika M., Pantić, Nikola, Poulsen, Christian Bjørn, Cuccaro, Annarosa, Del Principe, Maria Ilaria, Kulasekararaj, Austin, Ormazabal-Vélez, Irati, Busca, Alessandro, Demirkan, Fatih, Ijaz, Marriyam, Klimko, Nikolai, Stoma, Igor, Khostelidi, Sofya, Fernández, Noemí, Omrani, Ali S, Bergantim, Rui, De Jonge, Nick, Fouquet, Guillemette, Navrátil, Milan, Abu-Zeinah, Ghaith, Samarkos, Michail, Maertens, Johan, De Ramón, Cristina, Guidetti, Anna, Magyari, Ferenc, González-López, Tomás José, Lahmer, Tobias, Finizio, Olimpia, Ali, Natasha, Pinczés, László Imre, Lavilla-Rubira, Esperanza, Romano, Alessandra, Merelli, Maria, Delia, Mario, Calbacho, Maria, Meletiadis, Joseph, Antić, Darko, Hernández-Rivas, José-Ángel, Marques de Almeida, Joyce, Al-Khabori, Murtadha, Hoenigl, Martin, Tisi, Maria Chiara, Khanna, Nina, Barać, Aleksandra, Eisa, Noha, Di Blasi, Roberta, Liévin, Raphaël, Miranda-Castillo, Carolina, Bahr, Nathan C., Lamure, Sylvain, Papa, Mario Virgilio, Yahya, Ayel, Aujayeb, Avinash, Novák, Jan, Erben, Nurettin, Fernández-Galán, María, Ribera-Santa Susana, José-María, Rinaldi, Ikhwan, Fazzi, Rita, Piedimonte, Monica, Duléry, Rémy, Gonzaga, Yung, Soto-Silva, Andrés, Sapienza, Giuseppe, Serris, Alexandra, Drgoňa, Ľuboš, Groh, Ana, Serrano, Laura, Gavriilaki, Eleni, Tragiannidis, Athanasios, Prattes, Juergen, Coppola, Nicola, Otašević, Vladimir, Mladenović, Miloš, Mitrović, Mirjana, Mišković, Bojana, Jindra, Pavel, Zompi, Sofia, Sacchi, Maria Vittoria, Krekeler, Carolin, Infante, Maria Stefania, García-Bordallo, Daniel, Çolak, Gökçe Melis, Mayer, Jiří, Nygaard, Marietta, Hanáková, Michaela, Ráčil, Zdeněk, Bonanni, Matteo, Koehler, Philipp, Rahimli, Laman, Cornely, Oliver A., Pagano, Livio, Arellano-Orden, Elena [0000-0003-0581-8947], Salmanton-García, Jon, Marchesi, Francesco, Farina, Francesca, Weinbergerová, Barbora, Itri, Federico, Dávila-Valls, Julio, Martín-Pérez, Sonia, Glenthøj, Andreas, Hersby, Ditte Stampe, Gomes da Silva, Maria, Nunes Rodrigues, Raquel, López-García, Alberto, Córdoba, Raúl, Bilgin, Yavuz M., Falces-Romero, Iker, El-Ashwah, Shaimaa, Emarah, Ziad, Besson, Caroline, Kohn, Milena, Van Doesum, Jaap, Ammatuna, Emanuele, Marchetti, Monia, Labrador, Jorge, Zambrotta, Giovanni Paolo Maria, Verga, Luisa, Jaksic, Ozren, Nucci, Marcio, Piukovics, Klára, Cabirta-Touzón, Alba, Jiménez, Moraima, Arellano-Orden, Elena, Espigado, Ildefonso, Blennow, Ola, Nordlander, Anna, Meers, Stef, van Praet, Jens, Aiello, Tommaso Francesco, Garcia-Vidal, Carolina, Fracchiolla, Nicola, Sciumè, Mariarita, Seval, Guldane Cengiz, Žák, Pavel, Buquicchio, Caterina, Tascini, Carlo, Gräfe, Stefanie K., Schönlein, Martin, Adžić-Vukičević, Tatjana, Bonuomo, Valentina, Cattaneo, Chiara, Nizamuddin, Summiya, Čerňan, Martin, Plantefeve, Gaëtan, Prin, Romane, Szotkovski, Tomas, Collins, Graham P., Dargenio, Michelina, Petzer, Verena, Wolf, Dominik, Čolović, Natasha, Prezioso, Lucia, Valković, Toni, Passamonti, Francesco, Méndez, Gustavo-Adolfo, Sili, Uluhan, Vena, Antonio, Bavastro, Martina, Limongelli, Alessandro, Duarte, Rafael F., Ledoux, Marie-Pierre, Cvetanoski, Milche, Stojanoski, Zlate, Machado, Marina, Batinić, Josip, Magliano, Gabriele, Biernat, Monika M., Pantić, Nikola, Poulsen, Christian Bjørn, Cuccaro, Annarosa, Del Principe, Maria Ilaria, Kulasekararaj, Austin, Ormazabal-Vélez, Irati, Busca, Alessandro, Demirkan, Fatih, Ijaz, Marriyam, Klimko, Nikolai, Stoma, Igor, Khostelidi, Sofya, Fernández, Noemí, Omrani, Ali S, Bergantim, Rui, De Jonge, Nick, Fouquet, Guillemette, Navrátil, Milan, Abu-Zeinah, Ghaith, Samarkos, Michail, Maertens, Johan, De Ramón, Cristina, Guidetti, Anna, Magyari, Ferenc, González-López, Tomás José, Lahmer, Tobias, Finizio, Olimpia, Ali, Natasha, Pinczés, László Imre, Lavilla-Rubira, Esperanza, Romano, Alessandra, Merelli, Maria, Delia, Mario, Calbacho, Maria, Meletiadis, Joseph, Antić, Darko, Hernández-Rivas, José-Ángel, Marques de Almeida, Joyce, Al-Khabori, Murtadha, Hoenigl, Martin, Tisi, Maria Chiara, Khanna, Nina, Barać, Aleksandra, Eisa, Noha, Di Blasi, Roberta, Liévin, Raphaël, Miranda-Castillo, Carolina, Bahr, Nathan C., Lamure, Sylvain, Papa, Mario Virgilio, Yahya, Ayel, Aujayeb, Avinash, Novák, Jan, Erben, Nurettin, Fernández-Galán, María, Ribera-Santa Susana, José-María, Rinaldi, Ikhwan, Fazzi, Rita, Piedimonte, Monica, Duléry, Rémy, Gonzaga, Yung, Soto-Silva, Andrés, Sapienza, Giuseppe, Serris, Alexandra, Drgoňa, Ľuboš, Groh, Ana, Serrano, Laura, Gavriilaki, Eleni, Tragiannidis, Athanasios, Prattes, Juergen, Coppola, Nicola, Otašević, Vladimir, Mladenović, Miloš, Mitrović, Mirjana, Mišković, Bojana, Jindra, Pavel, Zompi, Sofia, Sacchi, Maria Vittoria, Krekeler, Carolin, Infante, Maria Stefania, García-Bordallo, Daniel, Çolak, Gökçe Melis, Mayer, Jiří, Nygaard, Marietta, Hanáková, Michaela, Ráčil, Zdeněk, Bonanni, Matteo, Koehler, Philipp, Rahimli, Laman, Cornely, Oliver A., and Pagano, Livio

Abstract

The COVID-19 pandemic heightened risks for individuals with hematological malignancies due to compromised immune systems, leading to more severe outcomes and increased mortality. While interventions like vaccines, targeted antivirals, and monoclonal antibodies have been effective for the general population, their benefits for these patients may not be as pronounced.

Published
2024

10. Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study

Author

Rodríguez-Medina, Carlos, Martínez-Cuadrón, David, Cano, Isabel, Gil, Cristina, Tormo, Mar, del Pilar Martínez-Sánchez, María, del Castillo, Teresa Bernal, Serrano-López, Josefina, Benavente, Celina, Herrera-Puente, Pilar, García-Boyero, Raimundo, Lavilla-Rubira, Esperanza, Amigo, Mª Luz, Sayas-Lloris, MªJose, Bergua-Burgues, Juan M, Pérez-Simón, José Antonio, Rodríguez, Gabriela, Espadana, Ana, Vidriales-Vicente, Belén, Fernández, Rosa, López-Lorenzo, Jose Luis, López, María, García-Fortes, María, Labrador Gómez, Jorge, Colorado-Araujo, Mercedes, Sossa-Melo, Claudia Lucia, Aguilar, Eliana, and Montesinos Fernández, Pau

Published
2020
Full Text
View/download PDF

11. AML-443 Clonal Evolution Analysis Using Next Generation Sequencing (NGS) Panel in a Cohort of 3,025 Patients With Acute Myeloid Leukemia (AML)

Author

Colmenares, Rafael, primary, Sargas, Claudia, additional, Álvarez, Noemí, additional, Chillón, María Carmen, additional, Carrillo-Cruz, Estrella, additional, Bilbao-Sieyro, Cristina, additional, de la Torre, Esther Prados, additional, Martínez-Cuadrón, David, additional, Rodríguez-Veiga, Rebeca, additional, Boluda, Blanca, additional, Gil, Cristina, additional, Bernal, Teresa, additional, Bergua, Juan Miguel, additional, Algarra, Lorenzo, additional, Tormo, Mar, additional, Martínez-Sánchez, Pilar, additional, Soria, Elena, additional, Serrano, Josefina, additional, Alonso-Domínguez, Juan Manuel, additional, García-Boyero, Raimundo, additional, Amigo, María Luz, additional, Herrera-Puente, Pilar, additional, Sayas, María José, additional, Lavilla-Rubira, Esperanza, additional, Calasanz, María José, additional, García-Sanz, Ramón, additional, Pérez-Simón, José Antonio, additional, Gómez-Casares, María Teresa, additional, Sánchez-García, Joaquín, additional, Barragán, Eva, additional, Martínez-López, Joaquín, additional, and Montesinos, Pau, additional

Published
2023
Full Text
View/download PDF

12. POSTER: AML-443 Clonal Evolution Analysis Using Next Generation Sequencing (NGS) Panel in a Cohort of 3,025 Patients With Acute Myeloid Leukemia (AML)

Author

Colmenares, Rafael, primary, Sargas, Claudia, additional, Álvarez, Noemí, additional, Chillón, María Carmen, additional, Carrillo-Cruz, Estrella, additional, Bilbao-Sieyro, Cristina, additional, de la Torre, Esther Prados, additional, Martínez-Cuadrón, David, additional, Rodríguez-Veiga, Rebeca, additional, Boluda, Blanca, additional, Gil, Cristina, additional, Bernal, Teresa, additional, Bergua, Juan Miguel, additional, Algarra, Lorenzo, additional, Tormo, Mar, additional, Martínez-Sánchez, Pilar, additional, Soria, Elena, additional, Serrano, Josefina, additional, Alonso-Domínguez, Juan Manuel, additional, García-Boyero, Raimundo, additional, Amigo, María Luz, additional, Herrera-Puente, Pilar, additional, Sayas, María José, additional, Lavilla-Rubira, Esperanza, additional, Calasanz, María José, additional, García-Sanz, Ramón, additional, Pérez-Simón, José Antonio, additional, Gómez-Casares, María Teresa, additional, Sánchez-García, Joaquín, additional, Barragán, Eva, additional, Martínez-López, Joaquín, additional, and Montesinos, Pau, additional

Published
2023
Full Text
View/download PDF

13. Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study

Author

Rodríguez-Arbolí, Eduardo, Martínez-Cuadrón, David, Rodríguez-Veiga, Rebeca, Carrillo-Cruz, Estrella, Gil-Cortés, Cristina, Serrano-López, Josefina, Bernal del Castillo, Teresa, Martínez-Sánchez, María del Pilar, Rodríguez-Medina, Carlos, Vidriales, Belén, Bergua, Juan Miguel, Benavente, Celina, García-Boyero, Raimundo, Herrera-Puente, Pilar, Algarra, Lorenzo, Sayas-Lloris, María José, Fernández, Rosa, Labrador, Jorge, Lavilla-Rubira, Esperanza, Barrios-García, Manuel, Tormo, Mar, Serrano-Maestro, Alfons, Sossa-Melo, Claudia Lucía, García-Belmonte, Daniel, Vives, Susana, Rodríguez-Gutiérrez, Juan Ignacio, Albo-López, Carmen, Garrastazul-Sánchez, María Paz, Colorado-Araujo, Mercedes, Mariz, José, Sanz, Miguel Ángel, Pérez-Simón, José Antonio, and Montesinos, Pau

Published
2021
Full Text
View/download PDF

14. Clinical outcomes after CPX ‐351 in patients with high‐risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

Author

Bernal, Teresa, primary, Moreno, Ainhoa Fernández, additional, de LaIglesia, Almudena, additional, Benavente, Celina, additional, García‐Noblejas, Ana, additional, Belmonte, Daniel García, additional, Riaza, Rosalía, additional, Salamero, Olga, additional, Foncillas, Maria Angeles, additional, Roldán, Alicia, additional, Concepción, Víctor Noriega, additional, González, Laura Llorente, additional, Bergua Burgués, Juan Miguel, additional, Lorente de Uña, Soraya, additional, Rodríguez‐Macías, Gabriela, additional, de la Fuente Burguera, Adolfo, additional, García Pérez, Maria José, additional, López‐Lorenzo, Jose Luis, additional, Martínez, Pilar, additional, Aláez, Concepción, additional, Callejas, Marta, additional, Martínez‐Chamorro, Carmen, additional, Roca, José Rifón, additional, Barciela, Lourdes Amador, additional, Mena Durán, Armando V., additional, Gómez Correcha, Karoll, additional, Lavilla Rubira, Esperanza, additional, Amigo, María Luz, additional, Vall‐llovera, Ferran, additional, Garrido, Ana, additional, García‐Fortes, María, additional, de Miguel Llorente, Dunia, additional, Leonardo, Anastasia Aules, additional, Cervero, Carlos, additional, Jordá, Rosa Coll, additional, Pérez‐Encinas, Manuel M., additional, Zarzuela, Marta Polo, additional, Figuera, Angela, additional, Rad, Guillermo, additional, Martínez‐Cuadrón, David, additional, and Montesinos, Pau, additional

Published
2023
Full Text
View/download PDF

15. Outcomes after intensive chemotherapy for secondary and myeloidrelated changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

Author

Martínez-Cuadrón, David, primary, Megías-Vericat, Juan E., additional, Gil, Cristina, additional, Bernal, Teresa, additional, Tormo, Mar, additional, Martínez-Sánchez, Pilar, additional, Rodríguez-Medina, Carlos, additional, Serrano, Josefina, additional, Herrera, Pilar, additional, Simón, José A. Pérez, additional, Sayas, María J., additional, Bergua, Juan, additional, Lavilla-Rubira, Esperanza, additional, Amigo, Maria Luz, additional, Benavente, Celina, additional, Lorenzo, Jose L. López, additional, Pérez-Encinas, Manuel M., additional, Vidriales, María B., additional, Colorado, Mercedes, additional, De Rueda, Beatriz, additional, García-Boyero, Raimundo, additional, Marini, Sandra, additional, García-Suárez, Julio, additional, López-Pavía, María, additional, Gómez-Roncero, Maria I., additional, Noriega, Víctor, additional, López, Aurelio, additional, Labrador, Jorge, additional, Cabello, Ana, additional, Sossa, Claudia, additional, Algarra, Lorenzo, additional, Stevenazzi, Mariana, additional, Solana-Altabella, Antonio, additional, Boluda, Blanca, additional, and Montesinos, Pau, additional

Published
2023
Full Text
View/download PDF

16. Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry

Author

Sargas, Claudia, Ayala Díaz, Rosa María, Larráyoz, María José, Chillón, María Carmen, Carrillo Cruz, Estrella, Bilbao Sieyro, Cristina, Prados de la Torre, Esther, Martínez Cuadrón, David, Rodríguez Veiga, Rebeca, Boluda, Blanca, Gil, Cristina, Bernal, Teresa, Bergua, Juan Miguel, Algarra, Lorenzo, Tormo, Mar, Martínez Sánchez, Pilar, Soriano, Elena, Serrano, Josefina, Alonso Domínguez, Juan Manuel, García Boyero, Raimundo, Amigo, Maria Luz, Herrera Puente, Pilar, Sayas, María José, Lavilla Rubira, Esperanza, Martínez López, Joaquín, Calasanz, María José, García Sanz, Ramón, Pérez Simón, José Antonio, Gómez Casares, María Teresa, Sánchez García, Joaquín, Barragán, Eva, Montesinos, Pau, Sargas, Claudia, Ayala Díaz, Rosa María, Larráyoz, María José, Chillón, María Carmen, Carrillo Cruz, Estrella, Bilbao Sieyro, Cristina, Prados de la Torre, Esther, Martínez Cuadrón, David, Rodríguez Veiga, Rebeca, Boluda, Blanca, Gil, Cristina, Bernal, Teresa, Bergua, Juan Miguel, Algarra, Lorenzo, Tormo, Mar, Martínez Sánchez, Pilar, Soriano, Elena, Serrano, Josefina, Alonso Domínguez, Juan Manuel, García Boyero, Raimundo, Amigo, Maria Luz, Herrera Puente, Pilar, Sayas, María José, Lavilla Rubira, Esperanza, Martínez López, Joaquín, Calasanz, María José, García Sanz, Ramón, Pérez Simón, José Antonio, Gómez Casares, María Teresa, Sánchez García, Joaquín, Barragán, Eva, and Montesinos, Pau

Abstract

Next–Generation Sequencing (NGS) implementation to perform accurate diagnosis in acute myeloid leukemia (AML) represents a major challenge for molecular laboratories in terms of specialization, standardization, costs and logistical support. In this context, the PETHEMA cooperative group has established the first nationwide diagnostic network of seven reference laboratories to provide standardized NGS studies for AML patients. Cross–validation (CV) rounds are regularly performed to ensure the quality of NGS studies and to keep updated clinically relevant genes recommended for NGS study. The molecular characterization of 2856 samples (1631 derived from the NGS–AML project; NCT03311815) with standardized NGS of consensus genes (ABL1, ASXL1, BRAF, CALR, CBL, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, GATA2, HRAS, IDH1, IDH2, JAK2, KIT, KRAS, MPL, NPM1, NRAS, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, TET2, TP53, U2AF1 and WT1) showed 97% of patients having at least one mutation. The mutational profile was highly variable according to moment of disease, age and sex, and several co–occurring and exclusion relations were detected. Molecular testing based on NGS allowed accurate diagnosis and reliable prognosis stratification of 954 AML patients according to new genomic classification proposed by Tazi et al. Novel molecular subgroups, such as mutated WT1 and mutations in at least two myelodysplasia–related genes, have been associated with an adverse prognosis in our cohort. In this way, the PETHEMA cooperative group efficiently provides an extensive molecular characterization for AML diagnosis and risk stratification, ensuring technical quality and equity in access to NGS studies., Bristol-Myers Squibb/Celgene, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Depto. de Medicina, Fac. de Medicina, TRUE, pub

Published
2023

17. Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19:matched-paired analysis in the EPICOVIDEHA registry

Author

Marchesi, Francesco, Salmanton-García, Jon, Buquicchio, Caterina, Itri, Federico, Besson, Caroline, Dávila-Valls, Julio, Martín-Pérez, Sonia, Fianchi, Luana, Rahimli, Laman, Tarantini, Giuseppe, Grifoni, Federica Irene, Sciume, Mariarita, Labrador, Jorge, Cordoba, Raul, López-García, Alberto, Fracchiolla, Nicola S., Farina, Francesca, Ammatuna, Emanuele, Cingolani, Antonella, García-Bordallo, Daniel, Gräfe, Stefanie K., Bilgin, Yavuz M., Dargenio, Michelina, González-López, Tomás José, Guidetti, Anna, Lahmer, Tobias, Lavilla-Rubira, Esperanza, Méndez, Gustavo-Adolfo, Prezioso, Lucia, Schönlein, Martin, Van Doesum, Jaap, Wolf, Dominik, Hersby, Ditte Stampe, Magyari, Ferenc, Van Praet, Jens, Petzer, Verena, Tascini, Carlo, Falces-Romero, Iker, Glenthøj, Andreas, Cornely, Oliver A., Pagano, Livio, Marchesi, Francesco, Salmanton-García, Jon, Buquicchio, Caterina, Itri, Federico, Besson, Caroline, Dávila-Valls, Julio, Martín-Pérez, Sonia, Fianchi, Luana, Rahimli, Laman, Tarantini, Giuseppe, Grifoni, Federica Irene, Sciume, Mariarita, Labrador, Jorge, Cordoba, Raul, López-García, Alberto, Fracchiolla, Nicola S., Farina, Francesca, Ammatuna, Emanuele, Cingolani, Antonella, García-Bordallo, Daniel, Gräfe, Stefanie K., Bilgin, Yavuz M., Dargenio, Michelina, González-López, Tomás José, Guidetti, Anna, Lahmer, Tobias, Lavilla-Rubira, Esperanza, Méndez, Gustavo-Adolfo, Prezioso, Lucia, Schönlein, Martin, Van Doesum, Jaap, Wolf, Dominik, Hersby, Ditte Stampe, Magyari, Ferenc, Van Praet, Jens, Petzer, Verena, Tascini, Carlo, Falces-Romero, Iker, Glenthøj, Andreas, Cornely, Oliver A., and Pagano, Livio

Abstract

Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report cases of breakthrough COVID-19 after prophylactic tixagevimab/cilgavimab from the EPICOVIDEHA registry). We identified 47 patients that had received prophylaxis with tixagevimab/cilgavimab in the EPICOVIDEHA registry. Lymphoproliferative disorders (44/47, 93.6%) were the main underlying HM. SARS-CoV-2 strains were genotyped in 7 (14.9%) cases only, and all belonged to the omicron variant. Forty (85.1%) patients had received vaccinations prior to tixagevimab/cilgavimab, the majority of them with at least two doses. Eleven (23.4%) patients had a mild SARS-CoV-2 infection, 21 (44.7%) a moderate infection, while 8 (17.0%) had severe infection and 2 (4.3%) critical. Thirty-six (76.6%) patients were treated, either with monoclonal antibodies, antivirals, corticosteroids, or with combination schemes. Overall, 10 (21.3%) were admitted to a hospital. Among these, two (4.3%) were transferred to intensive care unit and one (2.1%) of them died. Our data seem to show that the use of tixagevimab/cilgavimab may lead to a COVID-19 severity reduction in HM patients; however, further studies should incorporate further HM patients to confirm the best drug administration strategies in immunocompromised patients.

Published
2023

18. Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry

Author

Gilead Sciences, Salmanton-García, Jon, Marchesi, Francesco, Koehler, Philipp, Weinbergerová, Barbora, Čolović, Natasa, Falces-Romero, Iker, Buquicchio, Caterina, Farina, Francesca, Praet, Jens van, Biernat, Monika M., Itri, Federico, Prezioso, Lucia, Tascini, Carlo, Vena, Antonio, Romano, Alessandra, Delia, Mario, Dávila-Valls, Julio, Martín-Pérez, Sonia, Lavilla-Rubira, Esperanza, Adžić-vukičević, Tatjana, García-Bordallo, Daniel, López-García, Alberto, Criscuolo, Mariana, Petzer, Verena, Fracchiolla, Nicola S., Espigado, Ildefonso, Sili, Uluhan, Meers, Stef, Erben, Nurettin, Cattaneo, Chiara, Tragiannidis, Athanasios, Gavriilaki, Eleni, Schönlein, Martin, Mitrovic, Mirjana, Pantic, Nikola, Merelli, Maria, Labrador, Jorge, Hernández-Rivas, José Ángel, Glenthøj, Andreas, Fouquet, Guillemette, Príncipe, María Ilaria del, Dargenio, Michelina, Calbacho, María, Besson, Caroline, Kohn, Milena, Gräfe, Stefanie, Hersby, Ditte Stampe, Arellano-Orden, Elena, Çolak, Gökçe Melis, Wolf, Dominik, Marchetti, Monia, Nordlander, Anna, Blennow, Ola, Córdoba, Raúl, Mišković, Bojana, Mladenović, Miloš, Bavastro, Martina, Limongelli, Alessandro, Rahimli, Laman, Pagano, Livio, Cornely, Oliver A., Gilead Sciences, Salmanton-García, Jon, Marchesi, Francesco, Koehler, Philipp, Weinbergerová, Barbora, Čolović, Natasa, Falces-Romero, Iker, Buquicchio, Caterina, Farina, Francesca, Praet, Jens van, Biernat, Monika M., Itri, Federico, Prezioso, Lucia, Tascini, Carlo, Vena, Antonio, Romano, Alessandra, Delia, Mario, Dávila-Valls, Julio, Martín-Pérez, Sonia, Lavilla-Rubira, Esperanza, Adžić-vukičević, Tatjana, García-Bordallo, Daniel, López-García, Alberto, Criscuolo, Mariana, Petzer, Verena, Fracchiolla, Nicola S., Espigado, Ildefonso, Sili, Uluhan, Meers, Stef, Erben, Nurettin, Cattaneo, Chiara, Tragiannidis, Athanasios, Gavriilaki, Eleni, Schönlein, Martin, Mitrovic, Mirjana, Pantic, Nikola, Merelli, Maria, Labrador, Jorge, Hernández-Rivas, José Ángel, Glenthøj, Andreas, Fouquet, Guillemette, Príncipe, María Ilaria del, Dargenio, Michelina, Calbacho, María, Besson, Caroline, Kohn, Milena, Gräfe, Stefanie, Hersby, Ditte Stampe, Arellano-Orden, Elena, Çolak, Gökçe Melis, Wolf, Dominik, Marchetti, Monia, Nordlander, Anna, Blennow, Ola, Córdoba, Raúl, Mišković, Bojana, Mladenović, Miloš, Bavastro, Martina, Limongelli, Alessandro, Rahimli, Laman, Pagano, Livio, and Cornely, Oliver A.

Abstract

[Introduction] Molnupiravir and nirmatrelvir/ritonavir are antivirals used to prevent progression to severe SARS-CoV-2 infections and decrease hospitalisation and mortality rates. Nirmatrelvir/ritonavir was authorised in Europe in December 2021, whereas molnupiravir is not yet licensed in Europe as of February 2022. Molnupiravir may be an alternative to nirmatrelvir/ritonavir because it is associated with fewer drug-drug interactions and contraindications. A caveat for molnupiravir is the mode of action induces viral mutations. Mortality rate reduction with molnupiravir was less pronounced than that with nirmatrelvir/ritonavir in patients without haematological malignancy. Little is known about the comparative efficacy of the two drugs in patients with haematological malignancy at high-risk of severe COVID-19. Thus, molnupiravir and nirmatrelvir/ritonavir were compared in a cohort of patients with haematological malignancies., [Methods] Clinical data from patients treated with molnupiravir or nirmatrelvir/ritonavir monotherapy for COVID-19 were retrieved from the EPICOVIDEHA registry. Patients treated with molnupiravir were matched by sex, age (±10 years), and severity of baseline haematological malignancy to controls treated with nirmatrelvir/ritonavir., [Results] A total of 116 patients receiving molnupiravir for the clinical management of COVID-19 were matched to an equal number of controls receiving nirmatrelvir/ritonavir. In each of the groups, 68 (59%) patients were male; with a median age of 64 years (interquartile range [IQR] 53-74) for molnupiravir recipients and 64 years (IQR 54-73) for nirmatrelvir/ritonavir recipients; 56.9% (n=66) of the patients had controlled baseline haematological malignancy, 12.9% (n=15) had stable disease, and 30.2% (n=35) had active disease at COVID-19 onset in each group. During COVID-19 infection, one third of patients from each group were admitted to hospital. Although a similar proportion of patients in the two groups were vaccinated (molnupiravir n=77, 66% vs. nirmatrelvir/ritonavir n=87, 75%), more of those treated with nirmatrelvir/ritonavir had received four vaccine doses (n=27, 23%) compared with those treated with molnupiravir (n=5, 4%) (P<0.001). No differences were detected in COVID-19 severity (P=0.39) or hospitalisation (P=1.0). No statistically significant differences were identified in overall mortality rate (P=0.78) or survival probability (d30 P=0.19, d60 P=0.67, d90 P=0.68, last day of follow up P=0.68). Deaths were either attributed to COVID-19, or the infection was judged by the treating physician to have contributed to death., [Conclusions] Hospitalisation and mortality rates with molnupiravir were comparable to those with nirmatrelvir/ritonavir in high-risk patients with haematological malignancies and COVID-19. Molnupiravir is a plausible alternative to nirmatrelvir/ritonavir for COVID-19 treatment in patients with haematological malignancy.

Published
2023

19. Molnupiravir Compared to Nirmatrelvir/Ritonavir for COVID-19 in High-Risk Patients with Haematological Malignancy in Europe. A Matched-Paired Analysis from the Epicovideha Registry

Author

Salmanton-Garcia, Jon, primary, Marchesi, Francesco, additional, Koehler, Philipp, additional, Weinbergerova, Barbora, additional, Čolovic, Natasa, additional, Falces-Romero, Iker, additional, Buquicchio, Caterina, additional, Farina, Francesca, additional, Van Praet, Jens, additional, Biernat, Monika M., additional, Itri, Federico, additional, Prezioso, Lucia, additional, Tascini, Carlo, additional, Vena, Antonio, additional, Romano, Alessandra, additional, Delia, Mario, additional, Davila-Valls, Julio, additional, Martín-Pérez, Sonia, additional, Lavilla-Rubira, Esperanza, additional, Adzic, Tatjana N., additional, Garcia-Bordado, Daniel, additional, Lopez-Garcia, Alberto, additional, Criscuolo, Mariana, additional, Petzer, Verena, additional, Fracchiolla, Nicola S., additional, Espigado, Ildefonso, additional, Sili, Uluhan, additional, Meers, Stef, additional, Erben, Nurettin, additional, Cattaneo, Chiara, additional, Tragiannidis, Athanasios, additional, Gavriilaki, Eleni, additional, Schönlein, Martin, additional, Mitrovic, Mirjana, additional, Pantic, Nikola, additional, Merelli, Maria, additional, Labrador, Jorge, additional, Hernández-Rivas, Jose Angel, additional, Glenthoj, Andreas, additional, Fouquet, Guillemette, additional, del Principe, Maria Ilaria, additional, Dargenio, Michelina, additional, Calbacho, Maria, additional, Besson, Caroline, additional, Kohn, Milena, additional, Grafe, Stefanie K., additional, Hersby, Ditte Stampe, additional, Arellano, Elena, additional, Çolak, Gökçe Melis, additional, Wolf, Dominik, additional, Marchetti, Monia, additional, Nordlander, Anna, additional, Blennow, Ola, additional, Cordoba, Raul, additional, Miskovic, Bojana, additional, Mladenovic, Miloš, additional, Bavastro, Martina, additional, LIMONGELLI, Alessandro, additional, Rahimli, Laman, additional, Pagano, Livio, additional, and Cornely, Oliver A., additional

Published
2023
Full Text
View/download PDF

20. Nationwide Laboratory Network for AML Cross-Validated NGS Studies: Results from a Real-Life Cohort of the Pethema Group

Author

Sargas, Claudia, primary, Ayala, Rosa, additional, Chillon, Carmen, additional, Larrayoz, Maria Jose, additional, Carrillo, Estrella, additional, Bilbao, Cristina, additional, Yébenes, Manuel, additional, Llop, Marta, additional, Rapado, Inmaculada, additional, Garcia-Sanz, Ramon, additional, Vazquez, Iria, additional, Soria, Elena, additional, Sánchez-Sosa, Santiago, additional, Janusz, Kamila, additional, Botella, Carmen, additional, Serrano, Josefina, additional, Martinez-Cuadron, David, additional, Bergua, Juan-Miguel, additional, Amigo, Maria Luz, additional, Martinez Sanchez, Pilar, additional, Tormo, Mar, additional, Bernal, Teresa, additional, Herrera-Puente, Pilar, additional, García-Boyero, Raimundo, additional, Algarra, Lorenzo, additional, Sayas, Maria Jose, additional, Costilla-Barriga, Lisette, additional, Pérez-Santolalla, Esther, additional, Marchante, Inmaculada, additional, Lavilla-Rubira, Esperanza, additional, Noriega, Víctor, additional, Alonso Dominguez, Juan Manuel, additional, Sanz, Miguel A., additional, Sánchez, Joaquín, additional, Gómez-Casares, María Teresa, additional, Perez-Simon, Jose A., additional, Calasanz, María José, additional, González, Marcos, additional, Martínez-López, Joaquín, additional, Barragán, Eva, additional, and Montesinos, Pau, additional

Published
2021
Full Text
View/download PDF

21. Corrigendum to “Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study” [Leuk. Res. 92 (March) (2020) 106352]

Author

Rodríguez-Medina, Carlos, Martínez-Cuadrón, David, Cano, Isabel, Gil, Cristina, Tormo, Mar, del Pilar Martínez-Sánchez, María, del Castillo, Teresa Bernal, Serrano-López, Josefina, Benavente, Celina, Herrera-Puente, Pilar, García-Boyero, Raimundo, Lavilla-Rubira, Esperanza, Luz Amigo, Mª, Sayas-Lloris, MªJose, Bergua-Burgues, Juan M., Pérez-Simón, José Antonio, Rodríguez, Gabriela, Espadana, Ana, Vidriales-Vicente, Belén, Fernández, Rosa, López-Lorenzo, Jose Luis, López, María, García-Fortes, María, Gómez, Jorge Labrador, Colorado-Araujo, Mercedes, Sossa-Melo, Claudia Lucia, Aguilar, Eliana, and Montesinos, Pau

Published
2020
Full Text
View/download PDF

22. Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study

Author

Rodríguez-Arbolí, Eduardo, Martínez-Cuadrón, David, Rodríguez-Veiga, Rebeca, Carrillo-Cruz, Estrella, Gil-Cortés, Cristina, Serrano-López, Josefina, Bernal Del Castillo, Teresa, Martínez-Sánchez, María Del Pilar, Rodríguez-Medina, Carlos, Vidriales, Belén, Bergua, Juan Miguel, Benavente, Celina, García-Boyero, Raimundo, Herrera-Puente, Pilar, Algarra, Lorenzo, Sayas-Lloris, María José, Fernández, Rosa, Labrador, Jorge, Lavilla-Rubira, Esperanza, Barrios-García, Manuel, Tormo, Mar, Serrano-Maestro, Alfons, Sossa-Melo, Claudia Lucía, García-Belmonte, Daniel, Vives, Susana, Rodríguez-Gutiérrez, Juan Ignacio, Albo-López, Carmen, Garrastazul-Sánchez, María Paz, Colorado-Araujo, Mercedes, Mariz, José, Sanz, Miguel Ángel, Pérez-Simón, José Antonio, Montesinos, Pau, PETHEMA (Programa Español de Tratamientos en Hematología) and GETH (Grupo Español de Trasplante Hematopoyético y Terapia Celular) Cooperative Groups, Instituto de Salud Carlos III, and Centro de Investigación Biomédica en Red Cáncer (España)

Subjects
Oncology, medicine.medical_specialty, NPM1, European LeukemiaNet, Internal medicine, CEBPA, Immunology and Allergy, Medicine, Humans, Transplantation, Homologous, Cumulative incidence, Transplantation, Acute myeloid leukemia, business.industry, Remission Induction, Hematopoietic Stem Cell Transplantation, Myeloid leukemia, Cell Biology, Hematology, Confidence interval, Allogeneic stem cell transplant, Leukemia, Myeloid, Acute, Autologous stem cell transplant, Cytogenetic Analysis, Molecular Medicine, Stem cell, business, Nucleophosmin
Abstract

PETHEMA (Programa Español de Tratamientos en Hematología) and GETH (Grupo Espa~nol de Trasplante Hematopoyético y Terapia Celular) Cooperative Groups, Acute myeloid leukemia (AML) with intermediate risk cytogenetics (IRcyto) comprises a variety of biological entities with distinct mutational landscapes that translate into differential risks of relapse and prognosis. Optimal postremission therapy choice in this heterogeneous patient population is currently unsettled. In the current study, we compared outcomes in IRcyto AML recipients of autologous (autoSCT) (n = 312) or allogeneic stem cell transplantation (alloSCT) (n = 279) in first complete remission (CR1). Molecular risk was defined based on CEBPA, NPM1, and FLT3-ITD mutational status, per European LeukemiaNet 2017 criteria. Five-year overall survival (OS) in patients with favorable molecular risk (FRmol) was 62% (95% confidence interval [CI], 50-72) after autoSCT and 66% (95% CI, 41-83) after matched sibling donor (MSD) alloSCT (P = .68). For patients of intermediate molecular risk (IRmol), MSD alloSCT was associated with lower cumulative incidence of relapse (P < .001), as well as with increased nonrelapse mortality (P = .01), as compared to autoSCT. The 5-year OS was 47% (95% CI, 34-58) after autoSCT and 70% (95% CI, 59-79) after MSD alloSCT (P = .02) in this patient subgroup. In a propensity-score matched IRmol subcohort (n = 106), MSD alloSCT was associated with superior leukemia-free survival (hazard ratio [HR] 0.33, P = .004) and increased OS in patients alive 1 year after transplantation (HR 0.20, P = .004). These results indicate that, within IRcyto AML in CR1, autoSCT may be a valid option for FRmol patients, whereas MSD alloSCT should be the preferred postremission strategy in IRmol patients., Supported by a Río Hortega academic clinical fellowship (CM19/00194) from the Instituto de Salud Carlos III, Spain (E.R.A.). Additional funding has been provided by CIBERONC grants to J.P.S. (CB16/12/00480), M.M.S. (CB16/12/00369) and B.V. (CB16/12/00233).

Published
2020

23. Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project

Author

Sargas, Claudia, primary, Ayala, Rosa, additional, Chillón, María Carmen, additional, Larráyoz, María J., additional, Carrillo-Cruz, Estrella, additional, Bilbao, Cristina, additional, Yébenes-Ramírez, Manuel, additional, Llop, Marta, additional, Rapado, Inmaculada, additional, García-Sanz, Ramón, additional, Vázquez, Iria, additional, Soria, Elena, additional, Florido-Ortega, Yanira, additional, Janusz, Kamila, additional, Botella, Carmen, additional, Serrano, Josefina, additional, Martínez-Cuadrón, David, additional, Bergua, Juan, additional, Amigo, Mari Luz, additional, Martínez-Sánchez, Pilar, additional, Tormo, Mar, additional, Bernal, Teresa, additional, Herrera-Puente, Pilar, additional, García, Raimundo, additional, Algarra, Lorenzo, additional, Sayas, María J., additional, Costilla-Barriga, Lisette, additional, Pérez-Santolalla, Esther, additional, Marchante, Inmaculada, additional, Lavilla-Rubira, Esperanza, additional, Noriega, Víctor, additional, Alonso-Domínguez, Juan M., additional, Sanz, Miguel Á., additional, Sánchez-Garcia, Joaquín, additional, Gómez-Casares, María T., additional, Pérez-Simón, José A., additional, Calasanz, María J., additional, González-Díaz, Marcos, additional, Martínez-López, Joaquín, additional, Barragán, Eva, additional, and Montesinos, Pau, additional

Published
2020
Full Text
View/download PDF

24. Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?

Author

Martínez-Cuadrón, David, primary, Serrano, Josefina, additional, Gil, Cristina, additional, Tormo, Mar, additional, Martínez-Sánchez, Pilar, additional, Pérez-Simón, José A., additional, García-Boyero, Raimundo, additional, Rodríguez-Medina, Carlos, additional, López-Pavía, María, additional, Benavente, Celina, additional, Bergua, Juan, additional, Lavilla-Rubira, Esperanza, additional, Amigo, María L., additional, Herrera, Pilar, additional, Alonso-Domínguez, Juan M., additional, Bernal, Teresa, additional, Colorado, Mercedes, additional, Sayas, María J., additional, Algarra, Lorenzo, additional, Vidriales, María B., additional, Rodríguez-Macías, Gabriela, additional, Vives, Susana, additional, Pérez-Encinas, Manuel M., additional, López, Aurelio, additional, Noriega, Víctor, additional, García-Fortes, María, additional, Ramos, Fernando, additional, Rodríguez-Gutiérrez, Juan I., additional, Costilla-Barriga, Lisette, additional, Labrador, Jorge, additional, Boluda, Blanca, additional, Rodríguez-Veiga, Rebeca, additional, Martínez-López, Joaquín, additional, Sanz, Miguel A., additional, and Montesinos, Pau, additional

Published
2020
Full Text
View/download PDF

25. Management of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) - Data from the Spanish PNH Registry

Author

De La Iglesia Iñigo, Silvia, primary, Notario McDonell, Cristina, additional, Gaya Valls, Anna, additional, Cedena Romero, María Teresa, additional, Gómez Roncero, María Isabel, additional, Arrizabalaga Amunchastegui, Beatriz, additional, Monteserin Monteserin, Carmen, additional, Lavilla Rubira, Esperanza, additional, and Villegas Martínez, Ana María, additional

Published
2016
Full Text
View/download PDF

34. A phase 2, multicenter, clinical trial of CPX‐351 in older patients with secondary or high‐risk acute myeloid leukemia: PETHEMA‐LAMVYX.

Author

Rodríguez‐Arbolí, Eduardo, Rodríguez‐Veiga, Rebeca, Soria‐Saldise, Elena, Bergua, Juan M., Caballero‐Velázquez, Teresa, Arnán, Montserrat, Vives, Susana, Serrano, Josefina, Bernal, Teresa, Martínez‐Sánchez, Pilar, Tormo, Mar, Rodríguez‐Medina, Carlos, Herrera‐Puente, Pilar, Lavilla‐Rubira, Esperanza, Boluda, Blanca, Acuña‐Cruz, Evelyn, Cano, Isabel, Cáceres, Sara, Ballesteros, Juan, and Falantes, José

Subjects
*HEMATOPOIETIC stem cell transplantation, *SOMATIC mutation, *ACUTE myeloid leukemia, *OLDER patients, *VISUAL analog scale
Abstract

Background Methods Results Conclusions LAMVYX was a multicenter, single‐arm, phase 2 trial designed to validate the safety and efficacy of CPX‐351 in patients aged 60–75 years with newly diagnosed, secondary acute myeloid leukemia and to generate evidence on key issues not addressed in the preceding regulatory pivotal trial.The primary end point of the study was the complete remission (CR)/CR with incomplete hematologic recovery (CRi) rate after induction. Eligible patients were recommended to undergo allogeneic hematopoietic stem cell transplantation after the first consolidation cycle. Alternatively, patients could undergo up to six maintenance cycles with CPX‐351.Twenty‐nine patients (49%; 95% exact confidence interval [CI], 37%–62%) patients achieved a CR/CRi after one or two cycles of induction, with a measurable residual disease negativity rate of 67% as assessed by centralized, multiparameter flow cytometry. Among patients who had serial next‐generation sequencing analyses available, clearance of somatic mutations that were present at diagnosis was achieved in 7 (35%). The median follow‐up among survivors was 16.8 months (range, 8.7–24.3 months). The median event‐free survival was 3.0 months (95% CI, 1.4–7.3 months), and the median overall survival was 7.4 months (95% CI, 3.7–12.7 months). In landmark analyses at day +100 from diagnosis, the 1‐year overall and event‐free survival rate among patients who underwent allogeneic hematopoietic stem cell transplantation was 70% (95% CI, 47%–100%) and 70% (95% CI, 47%–100%), respectively. The corresponding values were 89% (95% CI, 71%–100%) and 44% (95% CI, 21%–92%), respectively, for patients who entered the maintenance phase. No significant longitudinal changes were observed in severity index or quality‐of‐life visual analog scale scores.The current data provide novel insights that might inform the clinical positioning and optimal use of CPX‐351, complementing previous results (ClinicalTrials.gov identifier NCT04230239). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study

Author

Martínez-Cuadrón, David, Megías-Vericat, Juan E., Serrano, Josefina, Martínez-Sánchez, Pilar, Arbolí, Eduardo Rodríguez, Gil, Cristina, Aguiar, Eliana, Bergua, Juan, López-Lorenzo, José L., Bernal, Teresa, Espadana, Ana, Colorado, Mercedes, Rodríguez-Medina, Carlos, López-Pavía, María, Tormo, Mar, Algarra, Jesus Lorenzo, Amigo, Mariluz, Sayas, María J., Labrador, Jorge, Rodríguez-Gutiérrez, Juan I., Benavente, Celina, Costilla-Barriga, Lissette, García-Boyero, Raimundo, Lavilla-Rubira, Esperanza, Vives, Susana, Herrera, Pilar, García-Belmonte, Daniel, Herráez-Albendea, María Mar, Esteves, Graça Vasconcelos, Gómez-Roncero, Maria I., Cabello, Ana, Bautista, Guiomar, Balerdi, Amaia, Mariz, José, Boluda, Blanca, Sanz, Miguel Á., and Montesinos, Pau

Abstract

Secondary acute myeloid leukemia (sAML) comprises a heterogeneous group of patients, and is associated with poor overall survival (OS). Weanalyzethe characteristics, treatment patterns and outcomes of sAML adult patients of the Programa Español de Tratamientos en Hematología (PETHEMA) registry. Overall, 6211 (72.9%) were de novoand 2310 (27.1%) sAML, divided into myelodysplastic syndrome(MDS-AML, 44%), MDS/myeloproliferative (MDS/MPN-AML, 10%), MPN-AML(11%), therapy-related (t-AML, 25%), and antecedent neoplasia without prior chemotherapy/radiotherapy (neo-AML, 9%). Compared to de novo, sAMLwere older (median age 69 years old), had more ECOG ≥2 (35%)or high-risk cytogenetics (40%), less FLT3-ITD (11%) and NPM1mutations (21%), andreceived less intensive chemotherapy regimens (38%) (all P<0.001).Median OS was higher in de novothan in sAML (10.9 vs 5.6 months, P<0.001); and shorterin sAML after hematologic disorder (MDS, MDS/MPN or MPN) as compared to t-AML and neo-AML (5.3 vs 6.1 vs 5.7 months, respectively, P=0.04).After intensive chemotherapy, median OS was better among de novoand neo-AML patients (17.2 and 14.6 months). No OS differences were observed afterhypomethylating agentsaccording to type of AML. sAML was as an independent adverse prognostic factor for OS. Weconfirmhigh prevalence and adverse features of sAML and we establish its independent adverse prognostic value.This study was registered at www.clinicaltrials.gov as #NCT02607059.

Published
2021
Full Text
View/download PDF

36. Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry.

Author

Aiello TF, Salmanton-Garcia J, Marchesi F, Weinbergerova B, Glenthoj A, Van Praet J, Farina F, Davila-Valls J, Martin-Perez S, El-Ashwah S, Schonlein M, Falces-Romero I, Labrador J, Sili U, Buquicchio C, Vena A, Plantefeve G, Petzer V, Biernat MM, Lahmer T, Espigado I, Van Doesum J, Blennow O, Piukovics K, Tascini C, Samarkos M, Bilgin YM, Fianchi L, Itri F, Valković T, Fracchiolla NS, Dargenio M, Jimenez M, Magyari F, Lopez-Garcia A, Prezioso L, Čolović N, Shumilov E, Abu-Zeinah G, Krekeler C, Lavilla-Rubira E, Papa MV, Gonzalez-Lopez TJ, Pinczes LI, Demirkan F, Ali N, Besson C, Fouquet G, Romano A, Hernandez-Rivas JA, Del Principe MI, Aujayeb A, Merelli M, Lamure S, De Almeida JM, Da Silva MG, Eisa N, Meletiadis J, Rinaldi I, Finizio O, Jaksic O, Delia M, Nizamuddin S, Marchetti M, Ijaz M, Machado M, Bailen-Almorox R, Čerňan M, Coppola N, Gavriilaki E, Cattaneo C, Groh A, Stojanoski Z, Erben N, Pantic N, Mendez GA, Di Blasi R, Meers S, De Ramon C, Bahr NC, Emarah Z, Varricchio G, Cvetanoski M, Garcia-Sanz R, Mitrovic M, Lievin R, Hanakova M, Račil Z, Vehreschild M, Tragiannidis A, Rodrigues RN, Garcia-Bordallo D, Cordoba R, Cabirta A, Nordlander A, Ammatuna E, Arellano E, Wolf D, Prin R, Limongelli A, Bavastro M, Colak GM, Grafe S, Hersby DS, Rahimli L, Cornely OA, Garcia-Vidal C, Pagano L, and Study Group E

Subjects
Humans, Male, Female, Aged, Middle Aged, Adult, Aged, 80 and over, Dexamethasone therapeutic use, Hematologic Neoplasms mortality, Hematologic Neoplasms drug therapy, Registries, COVID-19 mortality, COVID-19 complications, SARS-CoV-2 isolation & purification, COVID-19 Drug Treatment
Published
2024
Full Text
View/download PDF

37. Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry.

Author

Martínez-Cuadrón D, Megías-Vericat JE, Gil C, Bernal T, Tormo M, Martínez-Sánchez P, Rodríguez-Medina C, Serrano J, Herrera P, Simón JAP, Sayas MJ, Bergua J, Lavilla-Rubira E, Amigo ML, Benavente C, Lorenzo JLL, Pérez-Encinas MM, Vidriales MB, Colorado M, De Rueda B, García-Boyero R, Marini S, García-Suárez J, López-Pavía M, Gómez-Roncero MI, Noriega V, López A, Labrador J, Cabello A, Sossa C, Algarra L, Stevenazzi M, Solana-Altabella A, Boluda B, and Montesinos P

Subjects
Humans, Middle Aged, Aged, Retrospective Studies, Disease-Free Survival, Cytarabine, Remission Induction, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute drug therapy, Hematopoietic Stem Cell Transplantation
Abstract

Treatment options for patients with secondary acute myeloid leukemia (sAML) and AML with myeloid-related changes (AMLMRC) aged 60 to 75 years are scarce and unsuitable. A pivotal trial showed that CPX-351 improved complete remission with/without incomplete recovery (CR/CRi) and overall survival (OS) as compared with standard "3+7" regimens. We retrospectively analyze outcomes of 765 patients with sAML and AML-MRC aged 60 to 75 years treated with intensive chemotherapy, reported to the PETHEMA registry before CPX-351 became available. The CR/CRi rate was 48%, median OS was 7.6 months (95% confidence interval [CI]: 6.7-8.5) and event-free survival (EFS) 2.7 months (95% CI: 2-3.3), without differences between intensive chemotherapy regimens and AML type. Multivariate analyses identified age ≥70 years, Eastern Cooperative Oncology Group performance status ≥1 as independent adverse prognostic factors for CR/CRi and OS, while favorable/intermediate cytogenetic risk and NPM1 were favorable prognostic factors. Patients receiving allogeneic stem cell transplant (HSCT), autologous HSCT, and those who completed more consolidation cycles showed improved OS. This large study suggests that classical intensive chemotherapy could lead to similar CR/CRi rates with slightly shorter median OS than CPX-351.

Published
2024
Full Text
View/download PDF

38. Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry.

Author

Sargas C, Ayala R, Larráyoz MJ, Chillón MC, Carrillo-Cruz E, Bilbao-Sieyro C, Prados de la Torre E, Martínez-Cuadrón D, Rodríguez-Veiga R, Boluda B, Gil C, Bernal T, Bergua JM, Algarra L, Tormo M, Martínez-Sánchez P, Soria E, Serrano J, Alonso-Domínguez JM, García-Boyero R, Amigo ML, Herrera-Puente P, Sayas MJ, Lavilla-Rubira E, Martínez-López J, Calasanz MJ, García-Sanz R, Pérez-Simón JA, Gómez-Casares MT, Sánchez-García J, Barragán E, Montesinos P, and On Behalf Of Pethema Group

Abstract

Next-Generation Sequencing (NGS) implementation to perform accurate diagnosis in acute myeloid leukemia (AML) represents a major challenge for molecular laboratories in terms of specialization, standardization, costs and logistical support. In this context, the PETHEMA cooperative group has established the first nationwide diagnostic network of seven reference laboratories to provide standardized NGS studies for AML patients. Cross-validation (CV) rounds are regularly performed to ensure the quality of NGS studies and to keep updated clinically relevant genes recommended for NGS study. The molecular characterization of 2856 samples (1631 derived from the NGS-AML project; NCT03311815) with standardized NGS of consensus genes ( ABL1 , ASXL1 , BRAF , CALR , CBL , CEBPA , CSF3R , DNMT3A , ETV6 , EZH2 , FLT3 , GATA2 , HRAS , IDH1 , IDH2 , JAK2 , KIT , KRAS , MPL , NPM1 , NRAS , PTPN11 , RUNX1 , SETBP1 , SF3B1 , SRSF2 , TET2 , TP53 , U2AF1 and WT1 ) showed 97% of patients having at least one mutation. The mutational profile was highly variable according to moment of disease, age and sex, and several co-occurring and exclusion relations were detected. Molecular testing based on NGS allowed accurate diagnosis and reliable prognosis stratification of 954 AML patients according to new genomic classification proposed by Tazi et al. Novel molecular subgroups, such as mutated WT1 and mutations in at least two myelodysplasia-related genes, have been associated with an adverse prognosis in our cohort. In this way, the PETHEMA cooperative group efficiently provides an extensive molecular characterization for AML diagnosis and risk stratification, ensuring technical quality and equity in access to NGS studies.

Published
2023
Full Text
View/download PDF

39. Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project

Author

Sargas C, Ayala R, Chillón MC, Larráyoz MJ, Carrillo-Cruz E, Bilbao C, Yébenes-Ramírez M, Llop M, Rapado I, García-Sanz R, Vázquez I, Soria E, Florido-Ortega Y, Janusz K, Botella C, Serrano J, Martínez-Cuadrón D, Bergua J, Amigo ML, Martínez-Sánchez P, Tormo M, Bernal T, Herrera-Puente P, García R, Algarra L, Sayas MJ, Costilla-Barriga L, Pérez-Santolalla E, Marchante I, Lavilla-Rubira E, Noriega V, Alonso-Domínguez JM, Sanz MÁ, Sánchez-Garcia J, Gómez-Casares MT, Pérez-Simón JA, Calasanz MJ, González-Díaz M, Martínez-López J, Barragán E, and Montesinos P

Subjects
High-Throughput Nucleotide Sequencing, Humans, Mutation, Recurrence, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute genetics
Abstract

Next-Generation Sequencing has recently been introduced to efficiently and simultaneously detect genetic variations in acute myeloid leukemia. However, its implementation in the clinical routine raises new challenges focused on the diversity of assays and variant reporting criteria. To overcome this challenge, the PETHEMA group established a nationwide network of reference laboratories aimed to deliver molecular results in the clinics. We report the technical cross-validation results for next-generation sequencing panel genes during the standardization process and the clinical validation in 823 samples of 751 patients with newly diagnosed or refractory/relapse acute myeloid leukemia. Two cross-validation rounds were performed in seven nationwide reference laboratories in order to reach a consensus regarding quality metrics criteria and variant reporting. In the pre-standardization cross-validation round, an overall concordance of 60.98% was obtained with a great variability in selected genes and conditions across laboratories. After consensus of relevant genes and optimization of quality parameters the overall concordance rose to 85.57% in the second cross-validation round. We show that a diagnostic network with harmonized next-generation sequencing analysis and reporting in seven experienced laboratories is feasible in the context of a scientific group. This cooperative nationwide strategy provides advanced molecular diagnostic for acute myeloid leukemia patients of the PETHEMA group.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results